Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cartesian Therapeutics (RNAC) Debt Ratio: 2015-2023

Historic Debt Ratio for Cartesian Therapeutics (RNAC) over the last 8 years, with Dec 2023 value amounting to 0.09.

  • Cartesian Therapeutics' Debt Ratio fell 41.39% to 0.09 in Q4 2023 from the same period last year, while for Dec 2023 it was 0.09, marking a year-over-year decrease of 41.39%. This contributed to the annual value of 0.09 for FY2023, which is 41.39% down from last year.
  • According to the latest figures from Q4 2023, Cartesian Therapeutics' Debt Ratio is 0.09, which was down 46.11% from 0.17 recorded in Q2 2023.
  • In the past 5 years, Cartesian Therapeutics' Debt Ratio ranged from a high of 0.53 in Q3 2019 and a low of 0.09 during Q4 2023.
  • Moreover, its 3-year median value for Debt Ratio was 0.15 (2021), whereas its average is 0.15.
  • Per our database at Business Quant, Cartesian Therapeutics' Debt Ratio spiked by 58.90% in 2019 and then tumbled by 74.33% in 2020.
  • Cartesian Therapeutics' Debt Ratio (Quarterly) stood at 0.19 in 2019, then dropped by 21.07% to 0.15 in 2020, then increased by 6.98% to 0.16 in 2021, then dropped by 1.26% to 0.16 in 2022, then crashed by 41.39% to 0.09 in 2023.
  • Its last three reported values are 0.09 in Q4 2023, 0.17 for Q2 2023, and 0.17 during Q1 2023.